Literature DB >> 19375916

Eliminating latent tuberculosis.

Douglas B Young1, Hannah P Gideon, Robert J Wilkinson.   

Abstract

Tuberculosis is recognized as the world's leading bacterial cause of death. Yet 95% of infection is believed to exist in an asymptomatic 'latent' form that is defined not by the identification of bacteria, but by the host immune response in the form of reactivity to tuberculosis proteins in the tuberculin skin test. It seems likely that clinically defined latent tuberculosis actually represents a spectrum that runs from elimination of live bacilli to subclinical disease: hence, it might be unhelpful to use a single term to describe all these conditions. To support this view, here we focus on recent increased understanding of the heterogeneity in both bacillary physiology and host immune response that potentially illuminates new therapeutic and diagnostic approaches to this condition.

Entities:  

Mesh:

Year:  2009        PMID: 19375916     DOI: 10.1016/j.tim.2009.02.005

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  98 in total

Review 1.  Antigens for CD4 and CD8 T cells in tuberculosis.

Authors:  Cecilia S Lindestam Arlehamn; David Lewinsohn; Alessandro Sette; Deborah Lewinsohn
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-22       Impact factor: 6.915

2.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

3.  Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.

Authors:  Malcolm S Duthie; Rhea N Coler; John D Laurance; Lucas H Sampaio; Regiane M Oliveira; Ana Lucia M Sousa; Mariane M A Stefani; Yumi Maeda; Masanori Matsuoka; Masahiko Makino; Steven G Reed
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

4.  Clinical significance of interleukin-2/gamma interferon ratios in Mycobacterium tuberculosis-specific T-cell signatures.

Authors:  Franziska Suter-Riniker; Antonia Berger; Désirée Mayor; Pascal Bittel; Patricia Iseli; Thomas Bodmer
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

Review 5.  Latent tuberculosis: what the host "sees"?

Authors:  Hannah P Gideon; JoAnne L Flynn
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 6.  Heterogeneity in tuberculosis.

Authors:  Anthony M Cadena; Sarah M Fortune; JoAnne L Flynn
Journal:  Nat Rev Immunol       Date:  2017-07-24       Impact factor: 53.106

Review 7.  Sexual inequality in tuberculosis.

Authors:  Olivier Neyrolles; Lluis Quintana-Murci
Journal:  PLoS Med       Date:  2009-12-22       Impact factor: 11.069

8.  CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis.

Authors:  Zahra Hasan; Jacqueline M Cliff; Hazel M Dockrell; Bushra Jamil; Muhammad Irfan; Mussarat Ashraf; Rabia Hussain
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

9.  Biomarker changes associated with Tuberculin Skin Test (TST) conversion: a two-year longitudinal follow-up study in exposed household contacts.

Authors:  Rabia Hussain; Najeeha Talat; Firdaus Shahid; Ghaffar Dawood
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

Review 10.  The past and future of tuberculosis research.

Authors:  Iñaki Comas; Sebastien Gagneux
Journal:  PLoS Pathog       Date:  2009-10-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.